Amy E McKee insider trades: Biocryst Pharmaceuticals (BCRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Amy reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | BCRX | ↓ Sell | 11,180 | $8.97 | $100K | Direct | May 19, 2026 (1d) |
| Jun 24, 2024 | BCRX | ↓ Sell | 8,600 | $6.32 | $54K | Direct | Jun 25, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BCRX insiders
Open-market trades in the last 12 months
About Amy E McKee's insider trades
Amy E McKee is a director at Biocryst Pharmaceuticals (BCRX). Since Jun 24, 2024, Amy has reported no open-market purchases and 2 sales worth $155K on SEC Form 4. In the last 12 months: 1 sale ($100K).
Their filings also include grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.